These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18950882)

  • 1. Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy - A follow-up study.
    Zechmann CM; Aftab K; Didinger B; Giesel FL; Zamecnik P; Thieke C; Fütterer JJ; Kopp-Schneider A; Kauczor HU; Delorme S
    Radiother Oncol; 2009 Mar; 90(3):408-12. PubMed ID: 18950882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of peripheral zone and central gland volume in patients undergoing intensity-modulated radiotherapy.
    Zechmann CM; Simpfendörfer T; Giesel FL; Zamecnik P; Thieke C; Hielscher T; Meinzer HP; Delorme S
    J Comput Assist Tomogr; 2010; 34(5):739-45. PubMed ID: 20861778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
    Nishiyama T; Tomita Y; Takahashi K
    Urology; 2004 May; 63(5):917-21. PubMed ID: 15134981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
    Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
    Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer.
    Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Fujimoto K; Narazaki K; Mitsuya M; Takai Y; Yamada S
    Anticancer Res; 2009 May; 29(5):1831-4. PubMed ID: 19443412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
    Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric outcomes in prostate brachytherapy: is downsizing the prostate with androgen deprivation necessary?
    Gibbons EP; Jacobs BL; Smith RP; Beriwal S; Krishna K; Benoit RM
    Brachytherapy; 2009; 8(3):304-8. PubMed ID: 19217354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A semi-automated 2D/3D marker-based registration algorithm modelling prostate shrinkage during radiotherapy for prostate cancer.
    Budiharto T; Slagmolen P; Hermans J; Maes F; Verstraete J; Heuvel FV; Depuydt T; Oyen R; Haustermans K
    Radiother Oncol; 2009 Mar; 90(3):331-6. PubMed ID: 19013658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T.
    Heijmink SW; Scheenen TW; van Lin EN; Visser AG; Kiemeney LA; Witjes JA; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1446-53. PubMed ID: 19036532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Kirwan J; Mendenhall WM
    Laryngoscope; 2009 Oct; 119(10):1966-74. PubMed ID: 19688858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer.
    Namiki S; Ishidoya S; Ito A; Tochigi T; Numata I; Narazaki K; Yamada S; Takai Y; Arai Y
    Jpn J Clin Oncol; 2009 Nov; 39(11):732-8. PubMed ID: 19666904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.